Eli Lilly is about to report earnings. Here's what to expect
Wall Street expects strong third-quarter results driven by blockbusters Zepbound and Mounjaro, alongside early sales for obesity pill Foundayo.
Quick Look
Eli Lilly prepares to report third-quarter earnings and revenue, with Wall Street anticipating strong growth from obesity drug Zepbound and diabetes treatment Mounjaro, alongside initial sales figures for its new obesity pill, Foundayo.
AI-generated summary
Why It Matters
Eli Lilly launched its obesity pill, Foundayo, in April, adding to its portfolio of blockbuster metabolic treatments.
Eli Lilly is slated to report third-quarter earnings and revenue on Thursday, which will likely be fueled by its blockbuster obesity drug Zepbound and diabetes counterpart Mounjaro.
Here's what Wall Street is expecting, based on a survey of analysts by LSEG:
Earnings per share: $6.26 expected
Revenue: $22.61 billion expected
But investors will also be laser-focused on the launch of the company's obesity pill, Foundayo, which entered the market in April. Analysts forecast around $229 million in sales for the pill, StreetAccount estimates showed.
What to Watch
AI outlook — possibilities, not facts
Eli Lilly to report third-quarter earnings and revenue on Thursday
Very likely · Within days
Open Questions
- Will Eli Lilly beat Wall Street's $22.61 billion revenue expectation?
- What were the exact Q3 sales figures for Foundayo?





